Expression and immunoreactivity of HCV/HBV epitopes

doi:10.3748/wjg.v11.i41.6440

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 41

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2432)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-4) series, Tables (1-1) series.

Item

Count

PDF

231

HTML

1954

Figures (1-4)

126

Tables (1-1)

121

Sum=2432

Nov 7, 2005 (publication date) through May 6, 2024

Times Cited of This Article

Times Cited (5)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Viral Hepatitis

World J Gastroenterol. Nov 7, 2005; 11(41): 6440-6444
Published online Nov 7, 2005. doi: 10.3748/wjg.v11.i41.6440

Expression and immunoreactivity of HCV/HBV epitopes

Xin-Yu Xiong, Xiao Liu, Yuan-Ding Chen

Xin-Yu Xiong, Xiao Liu, Yuan-Ding Chen, Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming 650118, Yunnan Province, China

Author contributions: All authors contributed equally to the work.

Supported by the Yunnan Province Natural Science Foundation, No. 2003C0076M

Correspondence to: Professor Yuan-Ding Chen, The key Laboratory, Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming 650118, Yunnan Province, China. chenyd@imbcams.com.cn

Telephone: +86-871-8334689 Fax: +86-871-8334483

Received: March 31, 2005
Revised: April 26, 2005
Accepted: April 30, 2005
Published online: November 7, 2005

Abstract

AIM: To develop the epitope-based vaccines to prevent Hepatitis C virus (HCV) / Hepatitis B virus (HBV) infections.

METHODS: The HCV core epitopes C1 STNPKPQRKTKRNTNRRPQD (residuals aa2-21) and C2 VKFPGGGQIVGGVYLLPRR (residuals aa22-40), envelope epitope E GHRMAWDMMMNWSP (residuals aa315-328) and HBsAg epitope S CTTPAQGNSMFPSCCCTKPTDGNC (residuals aa124-147) were displayed in five different sites of the flock house virus capsid protein as a vector, and expressed in E. coli cells (pET-3 system). Immunoreactivity of the epitopes with anti-HCV and anti-HBV antibodies in the serum from hepatitis C and hepatitis B patients were determined.

RESULTS: The expressed chimeric protein carrying the HCV epitopes C1, C2, E (two times), L3C1-I2E-L1C2-L2E could react with anti-HCV antibodies. The expressed chimeric protein carrying the HBV epitopes S, I3S could react with anti-HBs antibodies. The expressed chimeric proteins carrying the HCV epitopes C1, C2, E plus HBV epitope S, L3C1-I2E-L1C2-L2E-I3S could react with anti-HCV and anti-HBs antibodies.

CONCLUSION: These epitopes have highly specific and sensitive immunoreaction and are useful in the development of epitope-based vaccines.

Keywords: HCV, HBV, Epitope-based vaccine, Recombinant, Immunoreactivity